Highbridge Capital Management’s ResMed RMD Stock Holding History

Highbridge Capital Management’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-30,000	Closed	-$3.12M	–	283
2019 Q1	$3.12M	Hold	30,000	–	–	0.1%	191
2018 Q4	$3.42M	Buy	30,000 +5,000	+20%	+$536K	0.1%	191
2018 Q3	$2.88M	Buy	+25,000	New	+$2.74M	0.07%	283
2018 Q2	–	Sell	-6,700	Closed	-$660K	–	1271
2018 Q1	$660K	Buy	+6,700	New	+$633K	0.01%	614
2015 Q3	–	Sell	-13,800	Closed	-$778K	–	1780
2015 Q2	$778K	Sell	13,800 -11,400	-45%	-$720K	0.01%	802
2015 Q1	$1.81M	Buy	+25,200	New	+$1.64M	0.03%	561

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's RMD Position: Q2 2019 in Review

Highbridge Capital Management sold out of ResMed (RMD) in Q2 2019, closing a stake of 22,400 shares — an estimated $2.33M sold.

Highbridge Capital Management first reported a position in RMD in Q3 2013 and held it in 11 quarters. The position peaked at $11M in Q3 2015. 485 funds tracked by Wall St. Rank hold RMD as of Q2 2019.

Highbridge Capital Management reported no remaining ResMed position as of Q2 2019 after selling out during the quarter.
Highbridge Capital Management sold 22,400 ResMed shares in Q2 2019, an estimated $2.33M.
Highbridge Capital Management first reported a position in ResMed in Q3 2013 and held it in 11 quarters.
Highbridge Capital Management's ResMed position peaked at $11M in Q3 2015.
485 funds tracked by Wall St. Rank held ResMed as of Q2 2019.

Based on Highbridge Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.